Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 06-Feb-24 4:42 PM View:  | Alam Kamran Chief Financial Officer | Taysha Gene Therapies, Inc. (TSHA) | 02-Feb-24 | Payment of Exercise | 1,288 | $1.51 | $1,944.88 | (< 1%) 842.23K to 840.94K | |
| 04-Jan-24 4:42 PM View: | Nagendran Sukumar President and Head of R&D Director | Taysha Gene Therapies, Inc. (TSHA) | 02-Jan-24 | Grant | 863,617 | -- | -- | 2523% 34.23K to 897.84K | |
| 04-Jan-24 4:43 PM View: | Alam Kamran Chief Financial Officer | Taysha Gene Therapies, Inc. (TSHA) | 02-Jan-24 | Grant | 590,413 | -- | -- | 234% 251.81K to 842.23K | |
| 04-Jan-24 4:41 PM View: | Nolan Sean P. Chief Executive Officer Director | Taysha Gene Therapies, Inc. (TSHA) | 02-Jan-24 | Grant | 1,184,690 | -- | -- | 77% 1.54M to 2.72M | |
| 20-Nov-23 7:35 AM View: | Manning Paul B 10% Owner | Taysha Gene Therapies, Inc. (TSHA) | 17-Nov-23 | Private Purchase | 100,000 | $1.63 | $163,000.00 | < 1% 23.42M to 23.52M | |
| 25-Aug-23 4:30 PM View: | Alam Kamran Chief Financial Officer | Taysha Gene Therapies, Inc. (TSHA) | 24-Aug-23 | Sale (Planned) | 33,000 | $2.33 | $76,890.00 | (11%) 291.04K to 258.04K | |
| 16-Aug-23 8:51 PM View: | Donenberg Philip B Director | Taysha Gene Therapies, Inc. (TSHA) | 16-Aug-23 | Private Purchase | 111,111 | $0.90 | $99,999.90 | 3704% 3.0K to 114.11K | |
| 16-Aug-23 8:53 PM View: | Stalfort Sean Director | Taysha Gene Therapies, Inc. (TSHA) | 16-Aug-23 | Purchase | 388,889 | $0.90 | $350,000.00 | 34% 1.16M to 1.54M | |
| 16-Aug-23 8:53 PM View: | Stalfort Sean Director | Taysha Gene Therapies, Inc. (TSHA) | 16-Aug-23 | Purchase | 388,889 | $0.90 | $350,000.00 | 25% 1.54M to 1.93M | |
| 16-Aug-23 8:52 PM View: | Nolan Sean P. Chief Executive Officer Director | Taysha Gene Therapies, Inc. (TSHA) | 16-Aug-23 | Private Purchase | 444,444 | $0.90 | $400,000.00 | 41% 1.09M to 1.54M | |
| 16-Aug-23 8:53 PM View: | Stalfort Sean Director | Taysha Gene Therapies, Inc. (TSHA) | 16-Aug-23 | Gift | 50,000 | -- | -- | 5% 1.11M to 1.16M | |
| 16-Aug-23 8:57 PM View: | Manning Paul B 10% Owner | Taysha Gene Therapies, Inc. (TSHA) | 16-Aug-23 | Private Purchase | 16,466,700 | $0.90 | $14,820,000.00 | 237% 6.95M to 23.42M | |
| 14-Jul-23 4:00 PM View: | Session R.A. II 10% Owner | Taysha Gene Therapies, Inc. (TSHA) | 13-Jul-23 | Sale | 5,344 | $0.70 | $3,740.80 | (< 1%) 9.16M to 9.15M | |
| 14-Jul-23 4:00 PM View: | Session R.A. II 10% Owner | Taysha Gene Therapies, Inc. (TSHA) | 12-Jul-23 | Sale | 80,528 | $0.71 | $57,029.90 | (< 1%) 9.24M to 9.16M | |
| 26-Jun-23 4:46 PM View: | Session R.A. II 10% Owner | Taysha Gene Therapies, Inc. (TSHA) | 23-Jun-23 | Sale | 18,100 | $0.70 | $12,735.20 | (< 1%) 9.26M to 9.24M | |
| 26-Jun-23 4:46 PM View: | Session R.A. II 10% Owner | Taysha Gene Therapies, Inc. (TSHA) | 22-Jun-23 | Sale | 10,508 | $0.70 | $7,383.97 | (< 1%) 9.27M to 9.26M | |
| 22-Jun-23 4:00 PM View: | Session R.A. II 10% Owner | Taysha Gene Therapies, Inc. (TSHA) | 21-Jun-23 | Sale | 138,962 | $0.70 | $97,634.70 | (1%) 9.41M to 9.27M | |
| 22-Jun-23 4:00 PM View: | Session R.A. II 10% Owner | Taysha Gene Therapies, Inc. (TSHA) | 20-Jun-23 | Sale | 295,653 | $0.71 | $210,209.00 | (3%) 9.7M to 9.41M | |
| 02-Jun-23 4:12 PM View: | Alam Kamran Chief Financial Officer | Taysha Gene Therapies, Inc. (TSHA) | 31-May-23 | Grant | 6,230 | -- | -- | 2% 284.81K to 291.04K | |
| 18-May-23 4:44 PM View: | Nagendran Sukumar President and Head of R&D Director | Taysha Gene Therapies, Inc. (TSHA) | 16-May-23 | Private Purchase | 5,000 | $0.68 | $3,400.00 | 17% 29.23K to 34.23K | |
| 08-Mar-23 7:38 PM View: | Session R.A. II 10% Owner | Taysha Gene Therapies, Inc. (TSHA) | 06-Mar-23 | Acquisition (other) | 251,296 | -- | -- | 3% 9.45M to 9.7M | |
| 06-Feb-23 9:12 PM View: | Alam Kamran Chief Financial Officer | Taysha Gene Therapies, Inc. (TSHA) | 02-Feb-23 | Grant | 18,691 | -- | -- | 7% 266.12K to 284.81K | |
| 02-Nov-22 4:09 PM View: | Manning Paul B Director 10% Owner | Taysha Gene Therapies, Inc. (TSHA) | 31-Oct-22 | Private Purchase | 1,500,000 | $2.00 | $3,000,000.00 | 28% 5.45M to 6.95M | |
| 24-Aug-22 4:47 PM View: | Alam Kamran Chief Financial Officer | Taysha Gene Therapies, Inc. (TSHA) | 23-Aug-22 | Sale (Planned) | 3,325 | $3.47 | $11,537.80 | (1%) 269.45K to 266.12K | |
| 22-Aug-22 8:05 PM View: | Alam Kamran Chief Financial Officer | Taysha Gene Therapies, Inc. (TSHA) | 22-Aug-22 | Sale (Planned) | 9,717 | $3.50 | $34,009.50 | (3%) 279.16K to 269.45K | |
| 22-Aug-22 8:05 PM View: | Alam Kamran Chief Financial Officer | Taysha Gene Therapies, Inc. (TSHA) | 19-Aug-22 | Sale (Planned) | 11,482 | $3.75 | $43,057.50 | (4%) 290.64K to 279.16K | |
| 22-Aug-22 8:05 PM View: | Alam Kamran Chief Financial Officer | Taysha Gene Therapies, Inc. (TSHA) | 18-Aug-22 | Sale (Planned) | 7,476 | $3.87 | $28,932.10 | (3%) 298.12K to 290.64K | |
| 07-Jul-22 4:30 PM View: | Prasad Suyash CMO and Head of R&D | Taysha Gene Therapies, Inc. (TSHA) | 06-Jul-22 | Sale (Planned) | 8,956 | $3.79 | $33,943.20 | (2%) 539.54K to 530.59K | |
| 07-Jul-22 4:30 PM View: | Prasad Suyash CMO and Head of R&D | Taysha Gene Therapies, Inc. (TSHA) | 05-Jul-22 | Sale (Planned) | 3,905 | $3.51 | $13,706.50 | (< 1%) 543.45K to 539.54K | |
| 01-Jul-22 6:55 PM View: | Prasad Suyash CMO and Head of R&D | Taysha Gene Therapies, Inc. (TSHA) | 01-Jul-22 | Sale (Planned) | 23,923 | $3.53 | $84,448.20 | (4%) 567.37K to 543.45K | |
| 01-Jul-22 6:55 PM View: | Prasad Suyash CMO and Head of R&D | Taysha Gene Therapies, Inc. (TSHA) | 30-Jun-22 | Sale (Planned) | 13,892 | $3.72 | $51,678.20 | (2%) 581.26K to 567.37K | |
| 01-Jul-22 6:55 PM View: | Prasad Suyash CMO and Head of R&D | Taysha Gene Therapies, Inc. (TSHA) | 29-Jun-22 | Sale (Planned) | 12,324 | $3.81 | $46,954.40 | (2%) 593.59K to 581.26K | |
| 04-Feb-22 8:28 AM View: | Manning Paul B Director 10% Owner | Taysha Gene Therapies, Inc. (TSHA) | 03-Feb-22 | Purchase | 26,602 | $7.84 | $208,560.00 | < 1% 5.42M to 5.45M | |
| 04-Feb-22 8:28 AM View: | Manning Paul B Director 10% Owner | Taysha Gene Therapies, Inc. (TSHA) | 03-Feb-22 | Purchase | 50,000 | $7.84 | $392,000.00 | < 1% 5.37M to 5.42M | |
| 04-Feb-22 8:28 AM View: | Manning Paul B Director 10% Owner | Taysha Gene Therapies, Inc. (TSHA) | 02-Feb-22 | Private Purchase | 58,000 | $7.77 | $450,660.00 | 1% 5.25M to 5.31M | |
| 03-Feb-22 9:21 AM View: | Nagendran Sukumar Director | Taysha Gene Therapies, Inc. (TSHA) | 02-Feb-22 | Private Purchase | 10,000 | $8.01 | $80,100.00 | 52% 19.23K to 29.23K | |
| 04-Feb-22 8:28 AM View: | Manning Paul B Director 10% Owner | Taysha Gene Therapies, Inc. (TSHA) | 02-Feb-22 | Purchase | 67,000 | $7.77 | $520,590.00 | 1% 5.31M to 5.37M | |
| 03-Feb-22 7:04 AM View: | Donenberg Philip B Director | Taysha Gene Therapies, Inc. (TSHA) | 02-Feb-22 | Private Purchase | 3,000 | $7.78 | $23,340.00 | 100% 0 to 3.0K | |
| 29-Nov-21 5:01 PM View: | Manning Paul B Director 10% Owner | Taysha Gene Therapies, Inc. (TSHA) | 24-Nov-21 | Market Purchase | 2,202 | $13.19 | $29,044.40 | < 1% 5.25M to 5.25M | (4%) |
| 24-Nov-21 7:58 AM View: | Manning Paul B Director 10% Owner | Taysha Gene Therapies, Inc. (TSHA) | 23-Nov-21 | Market Purchase | 20,000 | $12.54 | $250,800.00 | < 1% 5.23M to 5.25M | |
| 08-Dec-21 4:05 PM View: | Session R.A. II President and CEO Director 10% Owner | Taysha Gene Therapies, Inc. (TSHA) | 23-Nov-21 | Market Purchase | 42,518 | $12.44 | $529,102.00 | < 1% 9.43M to 9.47M | 16% |
| 20-Aug-21 5:52 PM View: | Alam Kamran Chief Financial Officer | Taysha Gene Therapies, Inc. (TSHA) | 20-Aug-21 | Market Sale (Planned) | 11,840 | $16.78 | $198,649.00 | (4%) 309.96K to 298.12K | 3% |
| 20-Aug-21 5:52 PM View: | Alam Kamran Chief Financial Officer | Taysha Gene Therapies, Inc. (TSHA) | 19-Aug-21 | Market Sale (Planned) | 9,967 | $16.47 | $164,175.00 | (3%) 319.93K to 309.96K | 1% |
| 20-Aug-21 5:52 PM View: | Alam Kamran Chief Financial Officer | Taysha Gene Therapies, Inc. (TSHA) | 18-Aug-21 | Market Sale (Planned) | 11,193 | $17.35 | $194,199.00 | (3%) 331.12K to 319.93K | 6% |
| 01-Jul-21 6:32 PM View: | Prasad Suyash CMO and Head of R&D | Taysha Gene Therapies, Inc. (TSHA) | 01-Jul-21 | Market Sale (Planned) | 19,706 | $21.12 | $416,191.00 | (3%) 613.29K to 593.59K | (< 1%) |
| 01-Jul-21 6:32 PM View: | Prasad Suyash CMO and Head of R&D | Taysha Gene Therapies, Inc. (TSHA) | 30-Jun-21 | Market Sale (Planned) | 20,076 | $21.79 | $437,494.00 | (3%) 633.37K to 613.29K | 3% |
| 01-Jul-21 6:32 PM View: | Prasad Suyash CMO and Head of R&D | Taysha Gene Therapies, Inc. (TSHA) | 29-Jun-21 | Market Sale (Planned) | 39,218 | $23.82 | $934,251.00 | (6%) 672.59K to 633.37K | 11% |
| 24-May-21 8:39 AM View: | Nolan Sean P. Director | Taysha Gene Therapies, Inc. (TSHA) | 20-May-21 | Market Purchase | 1,170 | $22.35 | $26,149.50 | < 1% 1.09M to 1.09M | (3%) |
| 17-May-21 7:48 AM View: | Manning Paul B Director 10% Owner | Taysha Gene Therapies, Inc. (TSHA) | 14-May-21 | Market Purchase | 12,000 | $20.98 | $251,760.00 | < 1% 5.22M to 5.23M | (< 1%) |
| 16-Feb-21 10:00 PM View: | Manning Paul B Director 10% Owner | Taysha Gene Therapies, Inc. (TSHA) | 31-Dec-20 | Gift | 80,000 | -- | -- | (2%) 5.3M to 5.22M |
